How AI and Decentralized Clinical Trials are Changing Biopharma

“As humans, we have limitations in being able to integrate and synthesize and look at data,” says venture capitalist John Orloff, formerly Global Head of R&D at Alexion Pharmaceuticals. “I think AI and machine learning technology will allow us to make better decisions and choices, and give us new insights into how to approach certain diseases.” More from Orloff inside…